Dr. Ou Joins ALKtALK 11/17/2024

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

RockSinCity
Published
Sai-Hong Ignatius Ou, Md, PhD, Clinical Professor, Division of Hematology/Oncology Medicine at the University of California Irvine School of Medicine joined ALKtALK on November 17, 2024. View this recording to hear, "What Lorlatinib as first-line treatment means for the ALK-positive community and current unmet needs in ALK-positive NSCLC." Dr. Ou shared his experience prescribing Lorlatinib as first line treatment for ALK-positive patients and the data that continues to drive this practice forward. Wondering what this may mean for you or your loved one? Whether you are newly diagnosed or a seasoned ALK thriver, this talk is for you. Press play to be informed and empowered.

ALK Positive is forever grateful for our guest experts and the time they give to share their Sunday evenings with us on ALKtALK. These gifts of time and expertise help to make our community a little smarter and a littler smaller. #knowledgeispower #morereserachmorelife #strongertogether

The purpose of ALKtALK is to provide the ALK-positive community with a platform to hear from leading experts with the latest data. ALK Positive does not endorse any one treatment and does not provide medical advice. Please be sure to share questions and concerns with your care team or second opinion physician.
Sign in or sign up to post comments.
Be the first to comment